CartiHeal has developed the Agili-C™, a biocompatible, coral-based implant designed for osteochondral joint repair. This innovative solution allows surgeons to insert a cylindrical implant into the patient’s knee, significantly reducing pain while enabling the regeneration of damaged cartilage. Suitable for a wide patient population, including those with mild to moderate osteoarthritis, the Agili-C™ offers a one-step, off-the-shelf treatment option.

Acquired by Smith+Nephew for up to $330 million, CartiHeal’s groundbreaking technology has received FDA breakthrough designation and approval, following clinical trials that demonstrated its effectiveness in improving joint function and patient outcomes.